Medadin (Colecalciferol)

Colecalciferol is first hydroxylated in the liver to 25‑hydroxyvitamin D, then in the kidney to the active hormone calcitriol. Calcitriol binds to nuclear vitamin D receptors in intestinal cells, stimulating production of calcium‑binding proteins, which increases intestinal uptake of calcium and phosphate, essential for bone mineralization.

The specific dose of Medadin is determined by the prescribing healthcare professional based on the patient’s age, serum vitamin D level, and clinical condition. Dosage may vary from low‑dose maintenance to higher therapeutic regimens, and should follow the prescriber’s instructions.

Safety data for colecalciferol in pregnancy and lactation are limited, and the product is not classified in a specific pregnancy category. Healthcare providers should evaluate the risk‑benefit profile before prescribing to pregnant or nursing women, and use only when clearly indicated.

To place an order, submit an enquiry on the Medadin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Medadin provides colecalciferol, the natural form of vitamin D3, which is widely regarded for its efficacy in raising serum 25‑hydroxyvitamin D levels. Compared with synthetic analogues such as calcitriol, colecalciferol has a longer half‑life and is generally used for routine supplementation rather than acute correction of severe deficiency.

Medadin should be stored at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Medadin is taken orally, usually with food or a glass of water to improve absorption. The tablet (or capsule) should be swallowed whole and not chewed or crushed unless directed by a healthcare professional. Follow the prescribing clinician’s guidance on timing and frequency.

The most serious adverse risk is hypercalcemia, which can cause nausea, vomiting, weakness, kidney stones, and cardiac arrhythmias. Patients with disorders affecting calcium metabolism, such as sarcoidosis or severe renal disease, are at higher risk and should be monitored closely.

Medadin should be avoided in individuals with known hypersensitivity to colecalciferol or any excipients, and in patients with hypercalcemia, hypervitaminosis D, or severe renal impairment unless specifically directed by a physician. Consultation with a healthcare provider is essential before starting therapy.